Prognostic factors in leptomeningeal metastases
Neuro Oncol
.
2021 Jul 1;23(7):1208-1209.
doi: 10.1093/neuonc/noab051.
Authors
Emilie Le Rhun
1
2
3
4
5
,
Patrick Devos
6
7
,
Johannes Weller
8
,
Katharina Seystahl
4
,
Francesca Mo
9
,
Anette Compter
10
,
Anna S Berghoff
11
,
Joost L M Jongen
12
,
Fabian Wolpert
4
,
Roberta Rudà
9
,
Dieta Brandsma
10
,
Martin van den Bent
12
,
Matthias Preusser
11
,
Ulrich Herrlinger
8
,
Michael Weller
4
Affiliations
1
University of Lille, Inserm, U-1192, Lille, France.
2
Neuro-Oncology, General and Stereotaxic Neurosurgery Service, University Hospital of Lille, Rue Emile Laine, Lille Cedex, France.
3
Breast Cancer Department, Oscar Lambret Center, Lille Cedex, France.
4
Department of Neurology, University Hospital and University of Zurich, Zurich, Switzerland.
5
Department of Neurosurgery, University Hospital and University of Zurich, Zurich, Switzerland.
6
Clinical Neuroscience Center and Comprehensive Cancer Center, University Hospital and University of Zurich, Zurich, Switzerland.
7
University of Lille, CHU Lille, ULR 2694 - METRICS: Évaluation des technologies de santé et des pratiques médicales, Lille, France.
8
Division of Clinical Neuro-Oncology, Department of Neurology, University Hospital Bonn, Venusberg Campus, Bonn, Germany.
9
Department of Neuro-Oncology, City of Health and Science University of Turin, Turin, Italy.
10
Department of Neuro-Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, the Netherlands.
11
Department of Medicine I, Division of Oncology, Medical University of Vienna, Vienna, Austria.
12
Brain Tumor Center at Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands.
PMID:
33830220
PMCID:
PMC8248845
DOI:
10.1093/neuonc/noab051
No abstract available
Publication types
Letter
Comment
MeSH terms
Humans
Meningeal Carcinomatosis* / diagnosis
Meningeal Neoplasms*
Prognosis